DIA 48th Annual Meeting
Click here to go to the previous page
Impact of Bayesian Methods in Medical Product Development
Track
:
Track 15: Statistical Science and Quantitative Thinking
Program Code:
367
Date:
Wednesday, June 27, 2012
Time:
1:30 PM to 3:00 PM
EST
CHAIR
:
Karen Price, Eli Lilly and Company, United States
PRESENTER
(S):
David Ohlssen, Novartis Pharmaceuticals Corporation, United States
Ram Tiwari, FDA, United States
Nelson Kinnersley, Roche Products ltd, United Kingdom
Description
Bayesian methods play an important role throughout the medical product development process. The DIA Bayesian Scientific Working Group, a coordinated effort from academia, regulatory, and industry, helps ensure that methods are well understood, accepted, and utilized.
Learning Objectives:
Discuss the importance of Bayesian methods in drug development
Recognize the impact the DIA Bayesian Scientific Working Group is having via collaboration across academia, regulatory, and industry
List examples of Bayesian methods improving medical product development.
Learning Objectives:
Discuss the importance of Bayesian methods in drug development
Recognize the impact the DIA Bayesian Scientific Working Group is having via collaboration across academia, regulatory, and industry
List examples of Bayesian methods improving medical product development.
This session is a part of:
Handout Online
